Posted by Michael Wonder on 02 Jun 2023
Mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma
31 May 2023 - NICE has published evidence based recommendations on the use of mosunetuzumab (Lunsumio) for the treatment of adults with relapsed or refractory follicular lymphoma.
Mosunetuzumab is not recommended for the treatment of adults with relapsed or refractory follicular lymphoma who have had 2 or more systemic therapies.
